Pharmacology Department, Theodor Bilharz Research Institute, P.O. box 30, Warrak El-Hadar, Giza, 12411, Imbaba, Egypt.
Nutrition and Food Sciences Department, National Research Centre, Dokki, Giza, 12622, Egypt.
BMC Complement Med Ther. 2024 Jan 23;24(1):51. doi: 10.1186/s12906-024-04351-2.
Cholestasis is an important predisposing factor for hepatocyte damage, liver fibrosis, primary biliary cirrhosis, and even liver failure. Silybum marianum L. (SM) plant is used in teas or eaten in some countries due to its antioxidant and hepatoprotective properties. Because of its low and poor oral bioavailability, so we improve the therapeutic activity of Silybum marianum L. extract (SM) by studying the potential effects of nanoformulation of Silybum marianium L. extract (nano-SM) on 17α-ethinylestradiol (EE)-induced intrahepatic cholestasis.
Thirty female Sprague-Dawley rats were divided into 5 groups (6 rats/group). Group I: Rats were received the treatment vehicle and served as normal group. Group II:Rats were injected daily with EE (10 mg/kg) for five successive days. Group III-V: Rats were injected daily with EE (10 mg/kg) and treated with either Ursodeoxycholic acid (UDCA) (40 mg/kg), SM (100 mg/kg) and nano-SM (100 mg/kg) orally once/day throughout the trialfor five successive days, respectively.
Nano-SM greatly dampened the increase in serum levels of total and direct bilirubin, alanine aminotransaminase, aspartate aminotransaminase, and alkaline phosphatase caused by EE. Furthermore, nano-SM increased the hepatic contents of reduced glutathione (GSH) and catalase (CAT) and also upregulated the relative hepatic gene expressions of Rho-kinase (ROCK-1), myosin light chain kinase (MLCK), and myosin phosphatase target subunit (MYPT1) compared to the EE-induced group. Administration of nano-SM reduced hepatic lipid peroxidation and downregulated the relative hepatic expressions of the nuclear factor-kappa B (NF-ҡB) and interleukin-1β (IL-1β). In addition, nano-SM improved the histopathological changes induced by EE.
Nano-SM possessed a superior effect over SM, which can be considered an effective protective modality against EE-induced cholestatic liver injury through its antioxidant, anti-inflammatory activities, and enhancing bile acid (BA) efflux.
胆汁淤积是肝细胞损伤、肝纤维化、原发性胆汁性肝硬化甚至肝衰竭的重要诱发因素。水飞蓟素(SM)植物因其抗氧化和保肝特性而被一些国家用于茶饮或食用。由于其口服生物利用度低且较差,因此我们通过研究水飞蓟素提取物(SM)纳米制剂的潜在作用来提高 SM 的治疗活性,以治疗 17α-乙炔雌二醇(EE)诱导的肝内胆汁淤积。
将 30 只雌性 Sprague-Dawley 大鼠分为 5 组(每组 6 只)。组 I:给予大鼠处理剂并作为正常组。组 II:大鼠连续 5 天每天注射 EE(10mg/kg)。组 III-V:大鼠连续 5 天每天注射 EE(10mg/kg),并分别用熊去氧胆酸(UDCA)(40mg/kg)、SM(100mg/kg)和纳米-SM(100mg/kg)口服治疗。
纳米-SM 极大地抑制了 EE 引起的血清总胆红素和直接胆红素、丙氨酸氨基转移酶、天冬氨酸氨基转移酶和碱性磷酸酶水平的升高。此外,纳米-SM 增加了肝组织中还原型谷胱甘肽(GSH)和过氧化氢酶(CAT)的含量,并上调了 Rho-kinase(ROCK-1)、肌球蛋白轻链激酶(MLCK)和肌球蛋白磷酸酶靶亚基(MYPT1)的相对肝基因表达,与 EE 诱导组相比。纳米-SM 降低了肝脂质过氧化作用,并下调了核因子-κB(NF-ҡB)和白细胞介素-1β(IL-1β)的相对肝表达。此外,纳米-SM 改善了 EE 诱导的组织病理学变化。
纳米-SM 比 SM 具有更好的效果,可通过其抗氧化、抗炎活性和增强胆汁酸(BA)外排来考虑作为 EE 诱导的胆汁淤积性肝损伤的有效保护方式。